keyword
MENU ▼
Read by QxMD icon Read
search

Cancer hematology oncology

keyword
https://www.readbyqxmd.com/read/28929484/post-marketing-research-and-its-outcome-for-novel-anticancer-agents-approved-by-both-the-fda-and-ema-between-2005-and-2010-a-cross-sectional-study
#1
Jean-David Zeitoun, Gabriel Baron, Alexandre Vivot, Ignacio Atal, Nicholas S Downing, Joseph S Ross, Philippe Ravaud
Post-marketing research in oncology has rarely been described. We aimed to characterize post-marketing trials for a consistent set of anticancer agents over a long period. We performed a cross-sectional analysis of post-marketing trials registered at ClinicalTrials.gov through September 2014 for novel anticancer agents approved by both the US Food and Drug Administration and the European Medicines Agency between 2005 and 2010. All relevant post-marketing trials were classified according to indication, primary outcome, starting date, sponsors, and planned enrollment...
September 20, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28927109/disease-progression-patterns-of-bevacizumab-responders-with-recurrent-malignant-gliomas
#2
Ju-Hwi Kim, Tae-Young Jung, Eu Chang Hwang, Sung-Hoon Jung, Shin Jung, In-Young Kim, Woo-Youl Jang, Kyung-Sub Moon, Kyung-Hwa Lee, Seul-Kee Kim
Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who responded to BEV therapy. From August 2011 to November 2015, 24 patients (18 glioblastoma cases and 6 anaplastic astrocytoma cases) were treated with BEV-based chemotherapy. In total, 6 patients were treated with BEV alone and 18 patients were treated with BEV combined with irinotecan...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28893309/efficacy-and-safety-of-controlled-release-oxycodone-naloxone-versus-controlled-release-oxycodone-in-korean-patients-with-cancer-related-pain-a-randomized-controlled-trial
#3
Kyung-Hee Lee, Tae Won Kim, Jung-Hun Kang, Jin-Soo Kim, Jin-Seok Ahn, Sun-Young Kim, Hwan-Jung Yun, Young-Jun Eum, Sung Ae Koh, Min Kyoung Kim, Yong Sang Hong, Jeong Eun Kim, Gyeong-Won Lee
BACKGROUND: Controlled-release oxycodone/naloxone (OXN-CR) maintains the effect of opioid-induced analgesia through oxycodone while reducing the occurrence rate of opioid-induced constipation through naloxone. The present study was designed to assess the non-inferiority of OXN-CR to controlled-release oxycodone (OX-CR) for the control of cancer-related pain in Korean patients. METHODS: In this randomized, open-labeled, parallel-group, phase IV study, we enrolled patients aged 20 years or older with moderate to severe cancer-related pain [numeric rating scale (NRS) pain score ≥4] from seven Korean oncology/hematology centers...
September 11, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28885879/infusion-room-based-transition-to-practice-model-for-teaching-cancer-systemic-therapy-management
#4
Jennifer M Duff, Merry-Jennifer Markham, Thomas J George, Julia L Close
PURPOSE: Oncology training requirements mandate that fellows demonstrate competence in delivery of cancer therapeutics, understand clinical indications for treatment, and manage toxicities by completion of training. An academic training environment may hinder fellows' engagement in prescribing, monitoring, and adjusting cancer therapy; thus, trainees may complete their fellowship with limited experience in developing such critical skills. To provide hands-on experience in cancer systemic therapy management, we created a novel infusion room-based rotation in the final year of training; here we report the structure, logistics, and evaluation of this innovative program...
September 8, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28879168/the-oncopig-cancer-model-an-innovative-large-animal-translational-oncology-platform
#5
REVIEW
Kyle M Schachtschneider, Regina M Schwind, Jordan Newson, Nickolas Kinachtchouk, Mark Rizko, Nasya Mendoza-Elias, Paul Grippo, Daniel R Principe, Alex Park, Nana H Overgaard, Gregers Jungersen, Kelly D Garcia, Ajay V Maker, Laurie A Rund, Howard Ozer, Ron C Gaba, Lawrence B Schook
Despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide. More than 8.2 million deaths were attributed to cancer in 2012, and it is anticipated that cancer incidence will continue to rise, with 19.3 million cases expected by 2025. The development and investigation of new diagnostic modalities and innovative therapeutic tools is critical for reducing the global cancer burden...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28875369/-personalized-oncology
#6
REVIEW
C Heining, P Horak, S Gröschel, H Glimm, S Fröhling
CLINICAL ISSUE: Innovative next generation sequencing (NGS) technologies and comprehensive sequencing investigations in large patient cohorts have paved the way for very promising personalized treatment strategies based on the molecular characteristics of individual tumors. STANDARD TREATMENT: Targeted therapies, such as tyrosine kinase inhibitors, antibodies and modern immunotherapeutic approaches are well established as monotherapy and combination therapy for many hematological and oncological malignancies...
September 5, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28865449/association-between-self-perception-of-aging-view-of-cancer-and-health-of-older-patients-in-oncology-a-one-year-longitudinal-study
#7
Sarah Schroyen, Pierre Missotten, Guy Jerusalem, M Van den Akker, F Buntinx, Stéphane Adam
BACKGROUND: Identifying older people affected by cancer who are more at risk of negative health outcomes is a major issue in health initiatives focusing on medical effectiveness. In this regard, psychological risk factors such as patients' perception of their own aging and cancer could be used as indicators to improve customization of cancer care. We hypothesize that more negative self-perception of aging (SPA) and view of cancer could be linked to worse physical and mental health outcomes in cancer patients...
September 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28856848/image-guided-imrt-with-simultaneous-integrated-boost-as-per-rtog-0529-for-the-treatment-of-anal-cancer
#8
Francesca Arcadipane, Pierfrancesco Franco, Manuela Ceccarelli, Gabriella Furfaro, Nadia Rondi, Elisabetta Trino, Stefania Martini, Giuseppe Carlo Iorio, Massimiliano Mistrangelo, Paola Cassoni, Patrizia Racca, Mario Morino, Umberto Ricardi
AIM: To report on clinical outcomes of simultaneous integrated boost intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy as per Radiation Therapy Oncology Group (RTOG) 0529 protocol in anal cancer patients. METHODS: Clinical stage T1-T4 N0-N3 anal cancer patients were submitted to concomitant chemoradiation. Patients with cT2N0 disease were prescribed 50.4 Gy/28 fractions to the gross tumor planning target volume (PTV) and 42 Gy/28 fractions to the elective nodal PTV...
August 30, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28856437/diagnosis-and-empirical-treatment-of-fever-of-unknown-origin-fuo-in-adult-neutropenic-patients-guidelines-of-the-infectious-diseases-working-party-agiho-of-the-german-society-of-hematology-and-medical-oncology-dgho
#9
REVIEW
W J Heinz, D Buchheidt, M Christopeit, M von Lilienfeld-Toal, O A Cornely, H Einsele, M Karthaus, H Link, R Mahlberg, S Neumann, H Ostermann, O Penack, M Ruhnke, M Sandherr, X Schiel, J J Vehreschild, F Weissinger, G Maschmeyer
Fever may be the only clinical symptom at the onset of infection in neutropenic cancer patients undergoing myelosuppressive chemotherapy. A prompt and evidence-based diagnostic and therapeutic approach is mandatory. A systematic search of current literature was conducted, including only full papers and excluding allogeneic hematopoietic stem cell transplant recipients. Recommendations for diagnosis and therapy were developed by an expert panel and approved after plenary discussion by the AGIHO. Randomized clinical trials were mainly available for therapeutic decisions, and new diagnostic procedures have been introduced into clinical practice in the past decade...
August 30, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28853528/-neuro-oncology-a-new-field-in-davidoff-cancer-center-at-rabin-medical-center
#10
REVIEW
Shlomit Yust-Katz, Dror Limon, Ramez Abu-Shkara, Tali Siegal
Neuro-oncology is a subspecialty attracting physicians from medical disciplines such as neurology, neurosurgery, pediatrics, oncology, and radiotherapy. It deals with diagnosis and management of primary brain tumors, as well as metastatic and non-metastatic neurological manifestations that frequently affect cancer patients including brain metastases, paraneoplastic syndromes and neurological complications of cancer treatment. A neuro-oncology unit was established in Davidoff Cancer Center at Rabin Medical Center...
August 2017: Harefuah
https://www.readbyqxmd.com/read/28842220/spiritual-needs-and-perception-of-quality-of-care-and-satisfaction-with-care-in-oncology-patients-a-multi-cultural-assessment
#11
Alan B Astrow, Gary Kwok, Rashmi K Sharma, Nelli Fromer, Daniel P Sulmasy
CONTEXT: Assessment and response to patients' spiritual concerns are crucial components of high quality supportive care. Better measures of spiritual needs across the cultural spectrum may help direct necessary interventions. OBJECTIVES: Assess spiritual needs in a racially/ethnically and religiously mixed sample of hematology and oncology outpatients and examine the association between spiritual needs and perception of quality of care and satisfaction with care...
August 22, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28837375/hematology-oncology-fellows-training-in-geriatrics-and-geriatric-oncology-findings-from-an-american-society-of-clinical-oncology-sponsored-national-survey
#12
Ronald J Maggiore, William Dale, Arti Hurria, Heidi D Klepin, Andrew Chapman, Efrat Dotan, Supriya G Mohile, Arash Naeim, Ajeet Gajra, Mary K Buss
PURPOSE: Older adults compose the majority of patients with cancer in the United States; however, it is unclear how well geriatrics or geriatric oncology training is being incorporated into hematology-oncology (hem-onc) fellowships. METHODS: A convenience sample of hem-onc fellows completed a (written or electronic) survey assessing their education, clinical experiences, and perceived proficiency in geriatric oncology during training; knowledge base in geriatric oncology; confidence in managing older adults with cancer; and general attitudes toward geriatric oncology principles...
August 24, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28832654/the-bereavement-experience-of-adolescents-and-early-young-adults-with-cancer-peer-and-parental-loss-due-to-death-is-associated-with-increased-risk-of-adverse-psychological-outcomes
#13
Liza-Marie Johnson, Carlos Torres, April Sykes, Deborah V Gibson, Justin N Baker
BACKGROUND: Adolescents commonly experience loss due to death, and perceived closeness to the deceased can often increase the intensity of bereavement. Adolescents and early young adult (AeYA) oncology patients may recall previous losses or experience new losses, possibly of other children with cancer, while coping with their own increased risk of mortality. The bereavement experiences of AeYA patients are not well described in the literature. METHODS AND FINDINGS: This analysis of bereavement sought to describe the prevalence and types of losses, the support following a death, and the impact of loss on AeYAs aged 13-21 years with malignant disease (or a hematologic disorder requiring allogeneic transplant)...
2017: PloS One
https://www.readbyqxmd.com/read/28829692/end-of-life-intensity-for-adolescents-and-young-adults-with-cancer-a-californian-population-based-study-that-shows-disparities
#14
Emily E Johnston, Elysia Alvarez, Olga Saynina, Lee Sanders, Smita Bhatia, Lisa J Chamberlain
PURPOSE: Cancer is the leading cause of nonaccidental death among adolescents and young adults (AYAs). High-intensity end-of-life care is expensive and may not be consistent with patient goals. However, the intensity of end-of-life care for AYA decedents with cancer-especially the effect of care received at specialty versus nonspecialty centers-remains understudied. METHODS: We conducted a retrospective, population-based analysis with the California administrative discharge database that is linked to death certificates...
September 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28828339/the-immune-response-of-vaccination-against-hepatitis-b-virus-in-iranian-patients-undergoing-chemotherapy
#15
Mohsen Meidani, Farzin Khorvash, Simin Hemati, Farzaneh Ashrafi, Behrouz Ataei, Dana Daneshmand
INTRODUCTION: Hepatitis B virus (HBV) infection and its complications are major public health problems. As it is hard to treat and control the chronic state, control of disease depends on the prevention especially by vaccination. There is an impaired immune response to vaccinations including HBV in patients with some malignancies. The aim of this study is to assess the response rate of patients undergoing chemotherapy to HBV vaccination. MATERIALS AND METHODS: All patients from two hematology/oncology clinics in Isfahan, Iran with the history of at least 1 month chemotherapy who had the inclusion criteria were enrolled in a case control study...
2017: Advanced Biomedical Research
https://www.readbyqxmd.com/read/28799485/monoclonal-antibodies-a-review
#16
Surjit Singh, Nitish Kumar, Pradeep Dwiwedi, Jaykaran Charan, Rimplejeet Kaur, Preeti Sidhu, Vinay Kumar Chugh
Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb, was first FDA approved therapeutic MAb for prevention of kidney transplant rejection. Since its approval in 1986, there has been decline in the further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of low grade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically...
August 9, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28780190/targeting-eph-ephrin-system-in-cancer-therapy
#17
REVIEW
Alessio Lodola, Carmine Giorgio, Matteo Incerti, Ilaria Zanotti, Massimiliano Tognolini
It is well established that the Eph/ephrin system plays a central role in the embryonic development, with minor implications in the physiology of the adult. However, it is overexpressed and deregulated in a variety of tumors, with a primary involvement in tumorigenesis, tumor angiogenesis, metastasis development, and cancer stem cell regeneration. Targeting the Eph/ephrin system with biologicals, including antibodies and recombinant proteins, reduces tumor growth in animal models of hematological malignancies, breast, prostate, colon, head and neck cancers and glioblastoma...
July 18, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28770610/amino-acid-profiles-as-potential-biomarkers-for-pediatric-cancers-a-preliminary-communication
#18
Anna Synakiewicz, Malgorzata Sawicka-Zukowska, Natalia Adrianowska, Grazyna Galezowska, Joanna Ratajczyk, Anna Owczarzak, Lucyna Konieczna, Teresa Stachowicz-Stencel
AIM: Childhood cancer remains one of the main cause of death in the pediatric population. Amino acids (AAs) level alterations in plasma are considered to play a role in carcinogenesis and further course of the disease. METHODS: Seventy-seven children with cancer, including 47 with hematological and 30 with solid tumors were enrolled in this study and compared with healthy children. Twenty-two plasma-free AAs were determined by HPLC with fluorometric detection. RESULTS: The results revealed significant decrease in glutamine levels for oncological patients and significant increase in aspartic acid, glutamic acid, asparagine, serine, citrulline, alanine, GABA, tryptophan, methionine, valine, phenylalanine and isoleucine levels in cancer children versus control...
August 3, 2017: Biomarkers in Medicine
https://www.readbyqxmd.com/read/28761384/new-pd-l1-inhibitors-in-non-small-cell-lung-cancer-impact-of-atezolizumab
#19
REVIEW
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezolizumab, its landmark studies, and ongoing trials. Atezolizumab is the first programmed death ligand 1 (PD-L1) inhibitor to receive US Food and Drug Administration (FDA) approval for metastatic NSCLC patients who have progressed on frontline chemotherapy...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28743264/recent-developments-in-immunotherapy-of-acute-myeloid-leukemia
#20
REVIEW
Felix S Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke, Marion Subklewe
The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the treatment of acute myeloid leukemia (AML) is hampered by various characteristics of the disease, including non-leukemia-restricted target antigen expression profile, low endogenous immune responses, and intrinsic resistance mechanisms of the leukemic blasts against immune responses. However, considerable progress has been made in this field in the past few years...
July 25, 2017: Journal of Hematology & Oncology
keyword
keyword
73361
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"